Evidence map›Paper›PMID 35037057›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2022

Circulating Levels of microRNA-122 and Hepatic Fat Change in Response to Weight-Loss Interventions: CENTRAL Trial.

Mengying Wang, Qiaochu Xue, Xiang Li, Knut Krohn, Stefanie Ziesche, Uta Ceglarek, Matthias Blüher, Maria Keller, Anat Yaskolka Meir, Yoriko Heianza and 3 more

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Metabolic diseases in the East Asian populations.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  9. Review
  10. Review
  11. Epigenetics in Precision Nutrition.Journal of personalized medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 4 countries.

Mengying WangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Qiaochu XueDepartment of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA,USA.
Xiang LiDepartment of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA,USA.
Knut KrohnCore Unit DNA Technologies, Medical Faculty, Leipzig University, Leipzig, Germany.
Stefanie ZiescheMedical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany.
Uta CeglarekInstitute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig Medical Center, Leipzig, Germany.ORCID 0000-0002-4034-5535
Matthias BlüherMedical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany.
Maria KellerMedical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany.
Anat Yaskolka MeirFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Yoriko HeianzaDepartment of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA,USA.
Peter KovacsMedical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany.ORCID 0000-0002-0290-5423
Iris ShaiFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Lu QiDepartment of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA,USA.ORCID 0000-0003-1832-695X
Tulane University · USBen-Gurion University of the Negev · ILLeipzig University · DEUniversity Hospital Leipzig · DE

Funding

Tulane COBRE in Cardiometabolic Diseases Clinical Research CoreP20GM109036 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI Ning Liu · 2016 to 2026
$25.3M
Nutrigenetics and Nutrigenomics for Precision Weight-Loss Diet InterventionsR01DK115679 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI Lu Qi · 2018 to 2026
$5.3M
Common Genetic Variation and Quantitative Diabetes TraitsR01DK078616 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI MEIGS, JAMES B · 2008 to 2014
$5.0M
Genetic Markers of CHD in Type 2 DiabetesR01HL071981 · NHLBI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI QI, LU · 2003 to 2012
$4.9M
TOPMed Omics of Type 2 Diabetes and Quantitative TraitsUM1DK078616 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI MANNING, ALISA KNODLE · 2021 to 2025
$3.8M
Rare Sequence Variation and Diabetes Quantitative TraitsU01DK078616 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI MEIGS, JAMES B · 2015 to 2019
$3.6M
Genome-wide interactions with diet patterns on long-term weight changeR21HL126024 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI QI, LU · 2015 to 2016
$421k
Dissecting the impact of forced displacement on Type Two DiabetesR21TW010790 · FIC · LEBANESE AMERICAN UNIVERSITY · PI QI, LU, ZALLOUA, PIERRE · 2018 to 2019
$308k
American Heart Association Scientist Development Award 0730094NChina Postdoctoral Science Foundation BX2021021FIC NIH HHS R21 TW010790NHLBI NIH HHS HL071981NHLBI NIH HHS R21 HL126024NIDDK NIH HHS DK115679NIDDK NIH HHS R01 DK078616NIDDK NIH HHS U01 DK078616NIDDK NIH HHS UM1 DK078616NIGMS NIH HHS P20 GM109036NIGMS NIH HHS P20GM109036
6 · The paper itself

Abstract

purposeLittle is known about the relations between changes in circulating microRNA-122 (miR-122) and liver fat in response to weight-loss interventions. We aimed to investigate the association between miR-122 and changes of hepatic fat content during 18-month diet and physical activity interventions.

methodsThe CENTRAL trial is an 18-month randomized, controlled trial among adults with abdominal obesity or dyslipidemia. Subjects were randomly assigned to a low-fat diet or a Mediterranean/low-carbohydrate diet. After 6 months of dietary intervention, each diet group was further randomized into added physical activity groups or no added physical activity groups for the following 12 months of intervention. The current study included 220 participants at baseline and 134 participants with repeated measurements on serum miR-122 and hepatic fat content over 18 months.

resultsSerum miR-122 significantly increased from baseline to 18 months, while no difference was observed across the 4 intervention groups. We found a significant association between miR-122 and hepatic fat content at baseline, as per unit increment in log-transformed miR-122 was associated with 3.79 higher hepatic fat content (P < 0.001). Furthermore, we found that higher elevations in miR-122 were associated with less reductions in hepatic fat percentage during 18-month interventions (β = 1.56, P = 0.002). We also found a significant interaction between changes in miR-122 and baseline fasting plasma glucose with hepatic fat content changes in 18 months (P interaction = 0.02).

conclusionsOur data indicate that participants with higher elevation in serum miR-122 may benefit less in reduction of hepatic fat content in response to diet and physical activity interventions.

Indexed as

Fatty LiverMicroRNAsAdultDiet, Carbohydrate-RestrictedDiet, Fat-RestrictedHumansWeight LossMicroRNAsMIRN122 microRNA, humanhepatic fatmicroRNA-122randomized controlled trialweight-loss interventions

Identifiers

PMID35037057
PMCPMC9016463
OpenAlexW4206039502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.